A Controlled Study of an Herbal Topical Patch in Treating Osteoarthritis (OA) of the Knee

This is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study of herbal patch in subjects with OA knee pain. The overall objective of this study is to evaluate the efficacy and safety of the patch in relieving OA knee pain.

Inclusion criteria

• Male or female between 40 and 70 years of age
• Medically cleared to participate by a site affiliated physician following a physical
• History of, or current diagnosis of, OA of the knee
• Evidence of idiopathic OA of at least one knee
• Subject Assessment of OA pain in target knee 40 - 75 mm (on the 100 mm VAS inclusive) in the index knee, on the WOMAC Pain composite subscale at Visit 1
• Subject Assessment of OA pain in non-index knee (if applicable) is ≤ 20mm
• Subject Global Assessment of OA Condition (5 pt categorical scale, 1 = very good to 5 = very poor) of grade 3-5 (i.e. fair, poor or very poor)
• Evidence of idiopathic OA of at least one knee as defined by the American College of Rheumatology Classification (ACR) of OA of the Knee

Exclusion criteria

• Grade 1 or Grade 4 severity of the index knee based on the Kellgren and Lawrence radiographic criteria
• Pain greater than 20 mm on the VAS in the non-index knee (either at rest or with movement)
• Prior injection or arthroscopy of study knee within 3 months
• Crystalline-induced synovitis (e.g. gout, pseudo gout, nonsteroid arthritis, hydroxyapatite deposit), acute inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, septic arthritis, fibromyalgia, systemic lupus, erythematosus collagen vascular disease or other types of inflammatory arthritis in the index knee
• Pain in either knee is of neurological origin
• An injury or surgery to the same body region within the prior 6 months or a lifetime history of 3 or more injuries/surgeries to the injured body region
• Signs of clinically important active inflammation of the study knee joint including redness, warmth, and/or a large, bulging effusion with the loss of normal contour at the screening and/or baseline visits
• Other criteria that - in the opinion of the investigator - may jeopardize the safety of the subject or the study results.